Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Inhibitors of cGMP-PDEs under study at Bayer

Feb. 9, 2000

RenaGel receives marketing approval in the E.U.

Feb. 4, 2000

Edex/Viridal preferred, more efficacious than other ED therapies

Feb. 2, 2000

Patients prefer Invicorp over Caverject

Feb. 1, 2000

New Zeria compounds with alpha1-adrenoceptor-blocking effects

Feb. 1, 2000

OPC-41061 + furosemide: additive diuretic effect + beneficial effect on electrolytes

Jan. 31, 2000

Bayer presents new candidate treatment for ED at ESIR

Jan. 31, 2000

IC-351 improves erectile response to visual stimulation in men with mild to moderate ED

Jan. 31, 2000

New formulation of Xatral receives European approvals

Jan. 28, 2000

Takeda files for ED treatment in Europe

Jan. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...